Grant M M, Burnett C M, Fein A M
Division of Pulmonary and Critical Care Medicine, Winthrop-University Hospital, Mineola, NY 11501.
Crit Care Med. 1991 Feb;19(2):211-7. doi: 10.1097/00003246-199102000-00017.
To determine whether the iv infusion of prostaglandin E1 (PGE1) could modify the early influx of neutrophils into bleomycin-injured lungs and if that would affect subsequent development of inflammation and fibrosis.
In vivo controlled animal study performed in a university hospital pulmonary research laboratory. Male Syrian golden hamsters (100- to 110-g body weight) were divided into four treatment groups: a) No treatment; b) intratracheal bleomycin plus PGE1 infusion; c) bleomycin plus saline infusion; d) PGE1 infusion only. PGE1 (180 ng/hr.100 g) or saline were infused iv 3 to 25 hr after intratracheal instillation of bleomycin sulfate (0.5 U/0.5 mL.100 g). Total and differential counts of cells recovered by lavage, lavage fluid protein, and lung total protein and hydroxyproline levels were measured from 6 hr to 30 days later.
PGE1 infusion reduced the influx of neutrophils 6 hr after bleomycin injury by 53% compared with saline infusion (p less than .0001), but increased inflammatory cell traffic after 24 hr for 15 days. At 4 days, protein recovered in lung lavage fluid was also decreased in PGE1-treated, bleomycin-injured animals, reflecting reduced injury to lung permeability barriers. Accumulation of lung collagen in the PGE1-treated, bleomycin-instilled hamsters tended to be lower than in the bleomycin-injured, saline-infused group at 15 and 30 days, although these differences did not achieve statistical significance. Despite this fact, greater than 33% of the animals in the PGE1-treated group died, possibly indicating an increased risk of sepsis in these animals.
PGE1 infusion can decrease early neutrophil traffic and reduce injury to the lung permeability barriers. However, this treatment augments late inflammatory events and does not significantly alter the development of fibrosis.
确定静脉输注前列腺素E1(PGE1)是否能改变博来霉素损伤肺中中性粒细胞的早期流入,以及这是否会影响随后炎症和纤维化的发展。
在大学医院肺部研究实验室进行的体内对照动物研究。雄性叙利亚金黄地鼠(体重100 - 110克)分为四个治疗组:a)不治疗;b)气管内注射博来霉素加PGE1输注;c)博来霉素加生理盐水输注;d)仅PGE1输注。在气管内滴注硫酸博来霉素(0.5 U/0.5 mL.100克)后3至25小时静脉输注PGE1(180 ng/hr.100克)或生理盐水。在6小时至30天后测量通过灌洗回收的细胞总数和分类计数、灌洗液蛋白以及肺总蛋白和羟脯氨酸水平。
与生理盐水输注相比,PGE1输注使博来霉素损伤后6小时中性粒细胞流入减少53%(p小于0.0001),但在24小时后持续15天增加了炎症细胞流量。在第4天,PGE1治疗的博来霉素损伤动物肺灌洗液中回收的蛋白也减少,反映出对肺通透性屏障的损伤减轻。在第15天和30天,PGE1治疗的博来霉素注入仓鼠肺胶原的积累倾向于低于博来霉素损伤的生理盐水输注组,尽管这些差异未达到统计学意义。尽管如此,PGE1治疗组中超过33%的动物死亡,这可能表明这些动物发生败血症的风险增加。
PGE1输注可减少早期中性粒细胞流量并减轻对肺通透性屏障的损伤。然而,这种治疗会加剧后期炎症事件,且不会显著改变纤维化的发展。